Dr. Schmader’s areas of research include herpes zoster, infections, and vaccines in older adults. He conducts translational, clinical trials and observational studies of zoster, influenza, and other infections funded by grants from the National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), Centers for Disease Control (CDC), VA Office of Research and Development, and Industry sources. He has played a pivotal role in the development of zoster vaccines in older adults. Dr. Schmader also performs research in medications and older adults, focusing on pharmacoepidemiology, optimal drug use and reduction of adverse drug reactions.
He is the Director of the NIA-funded P30 Duke Pepper Older Americans Independence Center and Co-PI of the NIAID funded Vaccine and Therapeutics Effectiveness Unit (VTEU) at Duke. He serves on the Working Groups for the Herpes Zoster, Influenza, and General Adult Immunization Guidelines for the US Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) and is the American Geriatrics Society liaison to the ACIP.
Education and Training
- Fellow in Geriatrics, Medicine, Duke University, 1986 - 1988
- Chief Medical Resident, Medicine, University of Wisconsin - Madison, 1983 - 1983
- Medical Resident, Medicine, University of Wisconsin - Madison, 1980 - 1983
- M.D., Wake Forest University, 1980
- Trajectories of care for Elderly Trauma Patients Requiring Mechanical Ventilation: A Depiction of their Year Post Trauma
- Deprescribing Central Nervous System Medications in Hospitalized Older Adults
- CIVICS Component C - Option 8 B.1
- Duke Creating ADRD Researchers for the Next Generation - Stimulating Access to Research in Residency Program (CARiNG-StARR)"
- IPA-Richard Sloane
- Transplant Infectious Diseases Interdisciplinary Research Training Grant (TIDIRTG)
- Deprescribing for Older Dialysis Patients
- CISA 07 Adult RCT COVID-19 Vaccination (Lead)
- CISA 2021-2022 - Clinical Consult - Opt 2
- CISA 2017 06 - Clinical Consult - Opt 2
- CISA 2018-2019 - Clinical Consult - Opt 2
- CISA Lead Site Task 3: Simultaneous RVZ and all V4 Vaccination (Lead)
- Physical Resiliencies: Indicators and Mechanisms in the Elderly Collaborative (PRIME Collaborative)
- VTEU TO #132 Base - HHSN272201300017I TO 75N93019F00132 Task Area A - FY.2020.A1B1C1D1.0123 - Option 2.A
- The AMPK/ULK1/p27Kip1 axis regulates autophagy and cell survival in aged satellite cells
- CISA Shingrix 2020 Lead Site Task 2
- VTEU Task Order 13-0045.C1D1.0062 - Task C Option 1